IN2013DN02555A - - Google Patents
Download PDFInfo
- Publication number
- IN2013DN02555A IN2013DN02555A IN2555DEN2013A IN2013DN02555A IN 2013DN02555 A IN2013DN02555 A IN 2013DN02555A IN 2555DEN2013 A IN2555DEN2013 A IN 2555DEN2013A IN 2013DN02555 A IN2013DN02555 A IN 2013DN02555A
- Authority
- IN
- India
- Prior art keywords
- compounds
- processes
- relates
- disorders
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates to compounds of formula (I) and (IA) and pharmaceutically acceptable salts thereof wherein R1 R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds methods of using these compounds in the treatment of various diseases and disorders processes for preparing these compounds and intermediates useful in these processes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38573310P | 2010-09-23 | 2010-09-23 | |
US201161533349P | 2011-09-12 | 2011-09-12 | |
PCT/US2011/052254 WO2012040139A1 (en) | 2010-09-23 | 2011-09-20 | Oxadiazole inhibitors of leukotriene production |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2013DN02555A true IN2013DN02555A (en) | 2015-08-07 |
Family
ID=44720163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2555DEN2013 IN2013DN02555A (en) | 2010-09-23 | 2011-09-20 |
Country Status (18)
Country | Link |
---|---|
US (1) | US8575201B2 (en) |
EP (1) | EP2619197B1 (en) |
JP (1) | JP5713511B2 (en) |
KR (1) | KR20130109122A (en) |
CN (1) | CN103261193A (en) |
AU (1) | AU2011305667A1 (en) |
BR (1) | BR112013008638A2 (en) |
CA (1) | CA2812449A1 (en) |
CL (1) | CL2013000788A1 (en) |
CO (1) | CO6710902A2 (en) |
EA (1) | EA201300389A1 (en) |
EC (1) | ECSP13012548A (en) |
IN (1) | IN2013DN02555A (en) |
MX (1) | MX2013003202A (en) |
PE (1) | PE20131398A1 (en) |
SG (1) | SG188604A1 (en) |
WO (1) | WO2012040139A1 (en) |
ZA (1) | ZA201301747B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2609092B1 (en) * | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
US8580825B2 (en) * | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
EP2619197B1 (en) | 2010-09-23 | 2015-08-05 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
AR089853A1 (en) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | OXADIAZOL INHIBITORS FROM THE PRODUCTION OF LEUCOTRIENS FOR COMBINATION THERAPY, PHARMACEUTICAL COMPOSITION, USE |
JP6424173B2 (en) * | 2013-02-04 | 2018-11-14 | ヤンセン ファーマシューティカ エヌ.ベー. | FLAP regulator |
PL2875736T3 (en) | 2013-11-26 | 2017-02-28 | Citrage | N-Carbamoylputrescine to enhance muscle protein synthesis |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE318811T1 (en) | 1999-08-06 | 2006-03-15 | Janssen Pharmaceutica Nv | INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES |
EP1653970A4 (en) * | 2003-08-13 | 2008-10-15 | Novartis Vaccines & Diagnostic | Gsk-3 inhibitors and uses thereof |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
US20070287736A1 (en) | 2004-10-18 | 2007-12-13 | Lin Chu | Diphenyl Substituted Alkanes as Flap Inhibitors |
GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US7977359B2 (en) * | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
CN101466677A (en) * | 2006-04-11 | 2009-06-24 | 默克公司 | Diaryl substituted alkanes |
AU2007265475B2 (en) | 2006-06-26 | 2010-08-19 | Amgen Inc. | Methods for treating atherosclerosis |
JP2010502615A (en) * | 2006-09-01 | 2010-01-28 | メルク エンド カムパニー インコーポレーテッド | Inhibitors of 5-lipoxygenase activating protein (FLAP) |
WO2008128335A1 (en) | 2007-04-20 | 2008-10-30 | Merck Frosst Canada Ltd. | Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
JP2010530419A (en) | 2007-06-20 | 2010-09-09 | メルク・シャープ・エンド・ドーム・コーポレイション | Diphenyl substituted alkane |
WO2009048547A1 (en) | 2007-10-10 | 2009-04-16 | Merck & Co., Inc. | Diphenyl substituted cycloalkanes |
DE102008037790A1 (en) * | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclic triazole derivatives |
CA2741666C (en) * | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
EP2393811A1 (en) | 2009-02-04 | 2011-12-14 | Pfizer Inc. | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives |
US9192603B2 (en) | 2010-05-12 | 2015-11-24 | Vanderbilt University | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2012024150A1 (en) * | 2010-08-16 | 2012-02-23 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
EP2609092B1 (en) * | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
EP2619197B1 (en) | 2010-09-23 | 2015-08-05 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
US8580825B2 (en) * | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
-
2011
- 2011-09-20 EP EP11761775.3A patent/EP2619197B1/en active Active
- 2011-09-20 SG SG2013020300A patent/SG188604A1/en unknown
- 2011-09-20 IN IN2555DEN2013 patent/IN2013DN02555A/en unknown
- 2011-09-20 CA CA2812449A patent/CA2812449A1/en not_active Abandoned
- 2011-09-20 AU AU2011305667A patent/AU2011305667A1/en not_active Abandoned
- 2011-09-20 CN CN2011800565586A patent/CN103261193A/en active Pending
- 2011-09-20 KR KR1020137007287A patent/KR20130109122A/en not_active Application Discontinuation
- 2011-09-20 WO PCT/US2011/052254 patent/WO2012040139A1/en active Application Filing
- 2011-09-20 MX MX2013003202A patent/MX2013003202A/en active IP Right Grant
- 2011-09-20 BR BR112013008638A patent/BR112013008638A2/en not_active IP Right Cessation
- 2011-09-20 JP JP2013530221A patent/JP5713511B2/en active Active
- 2011-09-20 US US13/237,112 patent/US8575201B2/en active Active
- 2011-09-20 EA EA201300389A patent/EA201300389A1/en unknown
- 2011-09-20 PE PE2013000629A patent/PE20131398A1/en not_active Application Discontinuation
-
2013
- 2013-03-07 ZA ZA2013/01747A patent/ZA201301747B/en unknown
- 2013-03-21 CL CL2013000788A patent/CL2013000788A1/en unknown
- 2013-03-22 CO CO13057875A patent/CO6710902A2/en not_active Application Discontinuation
- 2013-04-11 EC ECSP13012548 patent/ECSP13012548A/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20131398A1 (en) | 2013-12-19 |
WO2012040139A1 (en) | 2012-03-29 |
CL2013000788A1 (en) | 2013-06-28 |
MX2013003202A (en) | 2013-04-24 |
US8575201B2 (en) | 2013-11-05 |
EP2619197A1 (en) | 2013-07-31 |
CA2812449A1 (en) | 2012-03-29 |
ECSP13012548A (en) | 2013-06-28 |
CN103261193A (en) | 2013-08-21 |
CO6710902A2 (en) | 2013-07-15 |
EP2619197B1 (en) | 2015-08-05 |
EA201300389A1 (en) | 2013-09-30 |
JP5713511B2 (en) | 2015-05-07 |
BR112013008638A2 (en) | 2016-06-21 |
KR20130109122A (en) | 2013-10-07 |
AU2011305667A1 (en) | 2013-03-21 |
ZA201301747B (en) | 2014-08-27 |
JP2013537909A (en) | 2013-10-07 |
US20120295896A1 (en) | 2012-11-22 |
SG188604A1 (en) | 2013-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500457A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
IN2014MN00988A (en) | ||
PH12014502524B1 (en) | Carboxylic acid compounds | |
MD20140063A2 (en) | Benzothiazol-6-il acetic acid derivatives and their use for treating an HIV infection | |
UA104489C2 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
IN2015DN01119A (en) | ||
IN2014DN09352A (en) | ||
AU2011286276A8 (en) | Substituted Biphenylene Compounds and methods of use thereof for the treatment of viral diseases | |
IN2014DN09348A (en) | ||
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
CR20200286A (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
IN2012DN03182A (en) | ||
GB2511685A (en) | Muscarinic m1 receptor agonists | |
MX2012013274A (en) | Novel pyrimidine derivatives. | |
EA201300250A1 (en) | OXADIAZOL INHIBITORS OF LEUKOTRIEN PRODUCTION | |
MY169485A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
IN2014MN00697A (en) | ||
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
IN2013DN02555A (en) | ||
PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
IN2014KN01113A (en) | ||
MX2013006670A (en) | 2-carboxamide-4-piperazinyl-benzofuran derivative. | |
TN2013000122A1 (en) | Oxadiazole inhibitors of leukotriene production |